SkyKick Releases Major Platform Upgrades with New Intelligent Cloud Backup Product, Revamped Security Manager, and Next-Generation Migration Suites
27.7.2023 15:00:00 EEST | Business Wire | Press release
SkyKick (https://www.skykick.com), a global leader in cloud automation and management solutions for information technology service providers (ITSPs), today announced major enhancements to its Cloud Management Platform. New products and updates deliver enhanced data protection capabilities and personalized security insights, enabling ITSPs to meet the growing demand for robust security solutions and conversations in the SMB market. This marks the biggest platform update in the company’s ten-year history.
In an era dominated by data and AI, security is a top concern for 88% of SMB customers. Despite overall IT budgets staying flat or even declining, 42% of SMB business owners are open to investing more in security and data protection solutions. SMB appetite for MSP security services continues to grow against the backdrop of increased Microsoft 365 adoption (now with an estimated 382 million commercial users worldwide) and the proliferation of sensitive data that is being created in the cloud. ITSPs are struggling to meet demand.
“As pioneers in Microsoft 365 cloud data protection and security, we closely monitor usage and adoption trends among customers and partners," said SkyKick Co-CEO Todd Schwartz. "We’re seeing that in order for ITSPs to turn customer appetite into a successful security and data protection business, they need better and more intelligent tools. Our new products make it easy for ITSPs to not only meet customer demand, but also build a successful security practice – one that is easy to sell and easy to manage."
SkyKick is announcing a reimagined Cloud Backup product, offering Intelligent Data Protection for Microsoft 365. Among the exciting new features is SmartInsights, a new capability that enhances customer engagements through insights on data growth and protection trends. Today, customers are proactively seeking to understand their data protection status. With SmartInsights, ITSPs can tap into this customer appetite and transform data protection into a valuable differentiator.
Beyond SmartInsights, the new Cloud Backup introduces a user-centric architecture that streamlines ease of use for ITSPs. Examples include a new Groups Management functionality, which scales onboarding and offboarding processes. Extending the comprehensive Microsoft 365 coverage, protection for Microsoft Planner data is now also included. Collectively, the new Cloud Backup reimagines data protection for the modern ITSP, reducing time to resolution and increasing customer satisfaction.
Additionally, SkyKick has revamped its Security Manager solution, which now has millions of SMB end-users under management since its debut in the fall of 2022.
“For partners to fully deliver on the customer promise, they need to go beyond data protection. We created Security Manager to help partners be more proactive on security and grow a stronger practice,” said SkyKick Co-CEO Evan Richman. “Today, SkyKick is announcing SecurityRadar, a key innovation within Security Manager, purpose-built to arm 100,000 Microsoft cloud partners with data-driven security insights they can use to drive proactive and personalized customer engagement.”
Beyond SecurityRadar, Security Manager is upgrading its proprietary Microsoft Partner Center Connector (PCI) with new sync technology that is 2X faster and more automated - further simplifying day-to-day customer management and Microsoft-mandated GDAP compliance.
Early market reaction to the new updates has been very positive.
“Security is a top priority for Kinetix and New Charter Technologies. We are excited about the new innovations in Security Manager, and SecurityRadar is a game-changer for us,” said Robert Herbaugh, Security and Strategy Specialist at a leading MSP. “By facilitating strong customer conversations on security, it is helping us drive increased customer value and revenue growth.”
SkyKick is also announcing the next major version of its industry-leading Migration Suites. Between a streamlined setup, a more performant sync technology, and a highly configurable new migration experience – SkyKick has reimagined the “easiest way to Microsoft 365” with even more ease, flexibility, and control for the modern ITSP.
ITSPs, as well as their customers, deserve the assurance of knowing that their technology itself is certified to be robust and enterprise-grade. Building on its numerous other certifications, the SkyKick platform and system is now certified for ISO 27001, ISO 27701 and Data Pro.
SkyKick Co-CEO Evan Richman noted, “Our fundamental vision remains to be the platform of choice for ITSPs building and growing a business around Microsoft 365. With the major enhancements that we are announcing now across Migrations, Backup, Security Manager, and Certifications, we are confident that SkyKick will help IT partners to stay ahead of challenges and deliver a truly differentiated value in the channel.”
About SkyKick
SkyKick is a global provider of cloud management software for IT Services Providers. The company is headquartered in Seattle, Wash., and has offices in Amsterdam, Sydney, and Tokyo. Its products are designed to help build successful cloud businesses by making it easy and efficient for IT providers to migrate, backup, manage and secure their customers in the cloud. Over 30,000 partners worldwide use SkyKick’s products to accelerate their cloud business, and the company has won numerous awards including being named a Microsoft Partner of the Year, 2023 IAMCP Partner of the Year, Red Herring Top 100 North America winner and one of the “100 Best Companies to Work For” in Washington State. For more information visit www.skykick.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727023626/en/
Contact information
Paul Forecki
Voxus PR for SkyKick
skykickpr@voxuspr.com
253.208.3615
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
